Montesinos, Pau http://orcid.org/0000-0002-3275-5593
Roboz, Gail J.
Bulabois, Claude-Eric
Subklewe, Marion
Platzbecker, Uwe
Ofran, Yishai
Papayannidis, Cristina
Wierzbowska, Agnieszka
Shin, Ho Jin
Doronin, Vadim
Deneberg, Stefan
Yeh, Su-Peng
Ozcan, Mehmet Ali
Knapper, Steven
Cortes, Jorge
Pollyea, Daniel A. http://orcid.org/0000-0001-6519-4860
Ossenkoppele, Gert
Giralt, Sergio http://orcid.org/0000-0003-1944-5053
Döhner, Hartmut
Heuser, Michael
Xiu, Liang
Singh, Indrajeet
Huang, Fei
Larsen, Julie S.
Wei, Andrew H.
Funding for this research was provided by:
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Article History
Received: 24 July 2019
Revised: 11 December 2019
Accepted: 13 February 2020
First Online: 16 March 2020
Compliance with ethical standards
:
: GJR extended consulting or advisory services to Agios, Amphivena, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, MEI Pharma, Roche, Shire, Amgen, Astex Pharmaceuticals, Celator, Celgene, Cellectis, CTI, Genoptix, Juno Therapeutics, MedImmune, Novartis, Onconova Therapeutics, Pfizer, Sunesis Pharmaceuticals, received research funding from Abbvie (Inst), Agios (Inst), Astex Pharmaceuticals (Inst), Celgene (Inst), CTI (Inst), Karyopharm Therapeutics (Inst), MedImmune (Inst), MEI Pharma (Inst), Moffitt (Inst), Novartis (Inst), Onconova Therapeutics (Inst) Pfizer (Inst), Sunesis Pharmaceuticals (Inst), Tensha Therapeutics (Inst) and received travel, accommodations and other expenses from AstraZeneca, Shire, Astellas Pharma, Celator, Incyte, Roche, Amphivena, MEI Pharma, Astex Pharmaceuticals, Janssen, Juno Therapeutics. C-EB received support from Amgen, Astellas, Biosafe, Celgene, Chugai, Jazz Pharmaceuticals, Gentium, Gilead, Janssen, Keocyt, Macopharma, Mallinckrodt Pharmaceuticals, MSD, Mundipharma, OrpheliPharm, Pfizer, Pierre Fabre, Sandoz, Sanofi, Spectrum, Takeda, Teva, Therakos, Vifor pharma. MS received research funding from Amgen and Roche. MS received either travel reimbursements or consultant fees from Amgen, Celgene, Pfizer, and Seattle Genetics. UP has received honoraria from Celgene Corporation. AW received honoraria from Celgene. HD provided consultancy services to Agios, Amgen, Astex Pharmaceuticals, Celator, Celgene, Novartis, Roche, Seattle Genetics, Sunesis, and Tolero, and received research funding from Boehringer Ingelheim, Celgene, Novartis, Bristol-Myers Squibb, and Arog Pharmaceuticals research. JC received support from Ariad, Bristol-Myers Squibb, Novartis, and Teva and consultancy support from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. DAP is a member of advisory boards for Celgene and Pfizer. C.T.J. is an equity holder in Leuchemix Inc GO provided consultancy services to Novartis, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, Sunesis, Celgene, Karypharm, and Amgen, and received research support from Novartis, Johnson & Johnson, Celgene, Immunogene, and Becton Dickinson. AHW provided consultancy services to Novartis, Celgene, Servier, Abbvie, Roche, Amgen, and CTI, and received research funding from Abbvie, Novartis, Celgene, Servier, Ariad, and Amgen. LX, IS, FH, and JSL are employees of Janssen Research and development and may hold company stocks. PM, YO, CP, HJS, VD, SD, SPY, MAO, SK, SG, and MH declared no conflict of interest, financial or otherwise.